Investors are betting that Lilly will maintain its momentum. Its share price has climbed by a third since the start of 2024; ...

We came across a bullish thesis on Eli Lilly and Company (LLY) on Substack by Kontra. In this article, we will summarize the ...

Investors are worried Novo Nordisk's competition with Eli Lilly is heating up and that the first-to-market GLP-1 leader is ...

Looking at surging obesity drug sales, market share momentum, and an increased fair value estimate, here’s what we think of ...

Eli Lilly (LLY) shares rose on Wednesday as rival Novo Nordisk cut its full-year sales and profit guidance, reflecting ...

A U.S. federal judge has sided with a U.S. regulator's decision last year to take Eli Lilly’s blockbuster weight loss and ...

WeightWatchers isn’t the only company to feel the disruptive power of the weight loss drugs. London-listed but Irish-based ...

Novo Nordisk, which also makes Wegovy, fell victim to 'compounding' - a practice in the US that allows pharmacies to produce ...

Shares of Novo Nordisk climbed nearly 7% on Wednesday after the company said sales of its obesity drug Wegovy are expected to ...

We expect disappointing results in the first quarter will be balanced by higher-than-anticipated growth in the second half.

Mounjaro, a weight-loss drug by Eli Lilly, saw a huge jump in sales after its India launch. Sales of Mounjaro injections ...

A new federal ruling means that patients will no longer have access to cheaper versions of Eli Lilly weight loss and diabetes ...